Macrogen, Inc (Seoul, Korea) announces the formation of Axeq Technologies, a US-based division with operations and offices in the US, Europe and Asia. "Axeq" is a premium brand representing a whole new experience and industry-leading standards in DNA sequencing service. Axeq Technologies is dedicated to providing premier next-generation sequencing services and support to researchers around the world.
Leveraging the DNA sequencing and genotyping specialists from Macrogen's operations and large installed bases, Axeq offers a full menu of DNA sequencing applications, including exome, whole genome, targeted, pooled, RNA, transcriptome, and ChIP sequencing. In addition, by allocating our labor and material cost through our different divisions around the world, Axeq is able to provide very competitive pricing for big and small projects while maintaining a high-quality production process to generate publication-quality data.
Axeq offers both standard and custom applications using instrumentation and sample preparation platforms from Illumina, Life Technologies, Roche 454, Agilent Technologies, and Roche NimbleGen. Axeq has also established a large sequencing capacity. For example, Axeq has the capacity to produce over 100,000 exome sequences annually. As a result, Axeq provides a one- to two-month turnaround time guarantee even for large client projects.
Axeq Technologies also announces the launch of the Axeq "24/7, Mission-Critical Support" program. This support program includes 24 hours, 7 days a week support to our clients enabling researchers to maximize the benefits they receive from working with Axeq Technologies. With scientists and business personnel strategically located in three continents, the Axeq's 24/7, Mission-Critical Support program makes it possible for our clients to get immediate support around the clock, and no matter where they are located around the world.
"I would like to invite human geneticists worldwide to realize their dreams of understanding better of human genome and bring better cure and prevention to common and rare diseases," said Jeongsun Seo, MD. Ph.D., Chairman of Macrogen, Inc. and Axeq Technologies.
Source: Macrogen, Inc